Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a new clinical readout from the ongoing TUPELO Phase ...

Learn more about whether Immunocore Holdings plc or Recursion Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Former Google CEO Eric E. Schmidt predicted that artificial intelligence will be able to learn from itself within four years ...

Baystreet.ca News Commentary – The artificial intelligence in healthcare market is projected to expand from $17.2 billion in 2025 to $77.2 billion by 2035 as digital transformation and ...

Ethereum’s Fusaka upgrade introduces PeerDAS, new blob economics and key UX improvements that push deeper into the Surge, ...

The HackerEarth platform itself is pretty standard for online coding tests. You’ll have a code editor where you write your ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Etien Yovchev is the co-founder and managing partner of The Recursive, a tech media covering trends in Europe's AI economy.

These are some of the fastest, biggest gains I’ve seen in my career.  But they were just the appetizer.  The main course? The Genesis Mission – the single most important investment theme of ...

Infectious diseases such as bacterial, viral, fungal and parasitic diseases continue to have a significant impact on global health. Hence, knowledge on how infection spread, population vulnerable to ...

GreenGeeks claims to offer a '99.9% uptime guarantee', but that's no more than a hope, or a goal. If your site is down for ...